June 21, 2013

Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial.


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

This multicenter, randomized controlled trial assessed the efficacy, safety and incidence of CAV in de novo heart transplant patients receiving everolimus at two doses (1.5 mg/day or 3.0 mg/day in divided doses) with reduced-dose cyclosporine versus MMF with full-dose cyclosporine. The high dose everolimus group was terminated due to increased mortality. The lower dose everolimus with reduced-dose cyclosporine arm reduced the incidence of CAV at 12 months, a known major cause of graft failure and death. The everolimus arm was similar in terms of the combined endpoint (including rejection) and renal function in comparison to MMF. Thymoglobulin induction therapy in combination with the everolimus arm was associated with more infection related deaths and was considered inadvisable.

Cardiac Transplantation

Tags: , , , , , , , ,